RT Journal Article
SR Electronic
T1 Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.23.21262464
DO 10.1101/2021.08.23.21262464
A1 Winthrop, Kevin L.
A1 Skolnick, Alan W.
A1 Rafiq, Adnan M.
A1 Beegle, Scott H.
A1 Suszanski, Julian
A1 Koehne, Guenther
A1 Barnett-Griness, Ofra
A1 Bibliowicz, Aida
A1 Fathi, Reza
A1 Anderson, Patricia
A1 Raday, Gilead
A1 Eagle, Gina
A1 Ben-Yair, Vered Katz
A1 Minkowitz, Harold S.
A1 Levitt, Mark L.
A1 Gordon, Michael S.
YR 2022
UL http://medrxiv.org/content/early/2022/01/12/2021.08.23.21262464.abstract
AB Background Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit SARS-CoV-2 replication in vitro. We thus considered that opaganib could be beneficial for moderate to severe COVID-19 pneumonia. The objective of the study was to evaluate the effect of opaganib on supplemental oxygen requirements, time to hospital discharge and its safety in COVID-19 pneumonia hospitalized patients requiring supplemental oxygen.Methods This Phase 2a, randomized, double-blind, placebo-controlled study was conducted between July and December 2020 in eight sites in the USA. Forty-two enrolled patients received opaganib (n=23) or placebo (n=19) added to standard of care for up to 14 days and were followed up for 28 days after their last dose of opaganib/placebo.Results The relative decrease in total supplemental oxygen requirement from baseline to Day 14 was 61.6% in the opaganib versus 46.7% in the placebo arms. By Day 14, 50.0% of patients in the opaganib and 22.2% in the placebo group no longer required supplemental oxygen for at least 24 hours, while 86.4% and 55.6%, respectively, were discharged from hospital. The incidence of ≥ Grade 3 treatment-emergent adverse events was 17.4% and 33.3% in the opaganib and placebo groups, respectively. Three deaths occurred in each group.Conclusions In this proof-of-concept study, hypoxic, hospitalized patients receiving oral opaganib required less supplementary oxygen and had earlier hospital discharge, with no safety concerns arising. These findings support further evaluation of opaganib in this population.Summary Upon receiving opaganib, patients with COVID-19 pneumonia who were hospitalized and required supplemental oxygen showed symptomatic clinical improvement compared to placebo, with less supplemental oxygen requirement, resulting in earlier hospital discharge, and no safety concerns arising.Competing Interest StatementAida Bibliowicz is a full time employee at RedHill Biopharma Ltd., and has stock/stock options as part of employee compensation at RedHill Biopharma Ltd. Gilead Raday is a fulltime employee at RedHill Biopharma Ltd., and has stock options as part of employee compensation at RedHill Biopharma Ltd. Gina Eagle (GET Pharma Consulting, LLC) is a consultant to RedHill Biopharma Ltd. (consulting services included the review of the manuscript and contribution to content development). Michael S Gordon has received institutional support for the trial from RedHill Biopharma Ltd., Veru, Incyte, Fujifilm, Beigene, Kinevant, Neurorx, Syndax and Novartis; Is a consultant to RedHill Biopharma Ltd; Has received support for attending meetings/travel by RedHill Biopharma Ltd; Has patents planned/issued/pending at Caremission; Participates on a Data Safety Monitoring Boar/Advisory Board at Tracon; Is founder/owner at Caremission. Harold S Minkowitz has received study funding from Veru, Sorrento, Immune Bio, RedHill Biopharma Ltd., Regeneron, and Direct Biologics. Ofra Barnett-Griness is a statistical consultant for RedHill Biopharma Ltd. Patricia Anderson is a full time consultant as Head of Regulatory Affairs at RedHill Biopharma Ltd., and has stock options as part of being a full time consultant. Adnan Rafiq is a medical writer at RedHill Biopharma Ltd., and has received grants/contracts from Veru, Sorrento, and INmune Bio for research support. Reza Fathi is a full time consultant at Redhill Biopharma Ltd., and has stock options as part of being a full time consultant. Alan Skolnick has 500 shares at $7.08 in RedHill Biopharma Ltd. - on 08/May/2020 purchased by Alan Skolnik's wife. Julian Suszanski has received financial support for the study to Henry Ford Hospital. Vered Katz Ben-Yair is a full time consultant at RedHill Biopharma Ltd., and has stock options as part of being a full time consultant. Kevin Winthrop is a scientific consultant at RedHill Biopharma Ltd. Mark Levitt is a consultant at RedHill Biopharma Ltd., has a consultancy contract with RedHill Biopharma Ltd., has stock options at RedHill Biopharma Ltd., and is a co-inventor of several opaganib patents. Clinical TrialNCT04414618Funding StatementThe study was supported by RedHill Biopharma, Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Albany Medical Center, NY - WIRB HonorHealth - WIRB Baptist Hospital of Miami, FL - WIRB Ascension St. John Hospital, MI - Ascension St. John Hospital IRB Memorial Hermann Southeast Hospital, TX - WIRB Memorial Hermann - Memorial City Medical Center, TX - WIRB Henry Ford - Henry Ford Health System IRB Oregon Health & Science University - Oregon Health & Science University IRB I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn general, RedHill Biopharma Ltd. (RedHill) adopts ICMJE requirements regarding data sharing as detailed in its Data Sharing Plan. In accordance, the following statements apply to the publication titled Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial: Individual deidentified participant data (including data dictionaries) will currently not be shared Additional, related documents will be not available (e.g., study protocol, statistical analysis plan, etc.) Will the data become available and for how long? These are currently not available therefore this is not applicable. Since RedHill currently does not share individual deidentified participant data there are no access criteria wherein data will be shared (including with whom, for what types of analyses, and by what mechanism).